- Home
- SNT vs ANL Comparison
SNT vs ANL Comparison
Compare SNT & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNT
- ANL
- Stock Information
- Founded
- SNT 1965
- ANL 2004
- Country
- SNT Canada
- ANL Cayman Islands
- Employees
- SNT N/A
- ANL N/A
- Industry
- SNT Telecommunications Equipment
- ANL
- Sector
- SNT Telecommunications
- ANL
- Exchange
- SNT Nasdaq
- ANL Nasdaq
- Market Cap
- SNT 74.4M
- ANL 73.8M
- IPO Year
- SNT 1993
- ANL 2023
- Fundamental
- Price
- SNT $3.35
- ANL $1.84
- Analyst Decision
- SNT
- ANL Strong Buy
- Analyst Count
- SNT 0
- ANL 2
- Target Price
- SNT N/A
- ANL $9.00
- AVG Volume (30 Days)
- SNT 14.3K
- ANL 30.5K
- Earning Date
- SNT 06-12-2025
- ANL 05-13-2025
- Dividend Yield
- SNT N/A
- ANL N/A
- EPS Growth
- SNT N/A
- ANL N/A
- EPS
- SNT 0.11
- ANL N/A
- Revenue
- SNT $35,753,000.00
- ANL N/A
- Revenue This Year
- SNT N/A
- ANL N/A
- Revenue Next Year
- SNT N/A
- ANL N/A
- P/E Ratio
- SNT $29.95
- ANL N/A
- Revenue Growth
- SNT 9.03
- ANL N/A
- 52 Week Low
- SNT $1.27
- ANL $1.26
- 52 Week High
- SNT $3.97
- ANL $13.92
- Technical
- Relative Strength Index (RSI)
- SNT 51.14
- ANL 43.67
- Support Level
- SNT $3.29
- ANL $1.10
- Resistance Level
- SNT $3.55
- ANL $2.10
- Average True Range (ATR)
- SNT 0.15
- ANL 0.19
- MACD
- SNT 0.01
- ANL 0.00
- Stochastic Oscillator
- SNT 56.34
- ANL 67.27
About SNT Senstar Technologies Ltd.
Senstar Technologies Corp is a provider of comprehensive physical, video, and access control security products and solutions. Its perimeter intrusion detection systems (including fence sensors, buried sensors, and above-ground sensors), intelligent video management, video analytics, and access control offer a comprehensive suite of integrated solutions that reduce complexity, improve performance, and unify support.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.